Skip to main content

Table 1 Demographic profiles in patients with schizophrenia cases and controls (Mean ± SD)

From: Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia

Variables

Cases

(n=637)

Controls

(n=467)

t/X2

p value

Age (years)

47.52±10.61

44.94 ±13.63

− 3.392

0.001

Sex

 Female (%)

156 (24.5)

274 (58.7)

132.406

<0.001

 Male (%)

481 (75.5)

193 (41.3)

Years of education

9.30±6.81

9.66±5.33

0.955

0.340

Body mass index

24.45±4.00

25.14±4.18

2.538

0.011

Age of onset (years)

23.20±5.16

–

–

–

Duration of illness (years)

24.43 ± 10.52

–

–

–

Mean daily dose (mg/day)

(chlorpromazine equivalents)

391.72 ± 181.22

–

–

–

PANSS total score

60.81 ± 14.91

–

–

–

Positive symptoms

11.90 ± 5.15

–

–

–

Negative symptoms

23.25 ± 8.50

–

–

–

General psychopathology

25.66 ± 6.02

–

–

–

ApoA1 level (g/L)

1.53 ± 0.38

–

–

–

ApoB level (g/L)

0.89 ± 0.24

–

–

–

ApoA1/ApoB

1.82 ± 0.62

–

–

–